A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma

Zhejiang University

Status: Completed

Conditions: Neoplasms Pancreatic

Treatments: Procedure: pancreatic cancer surgery

Study type: Observational

Funder types: Other

Identifiers

NCT05547074

PSMPDAC

Details and patient eligibility

About

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.

Enrollment: 302 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Pathologically confirmed PDAC
2. Achievement of surgical resection (including radical or palliative surgery)

Exclusion criteria

1. Lost to follow-up
2. Simultaneous presence of other tumors
3. Died in three months after surgery

Trial design

302 participants in 2 patient groups

The training cohort

Description:

To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).

Treatment:

Procedure: pancreatic cancer surgery

The validation cohort

Description:

To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).

Treatment:

Procedure: pancreatic cancer surgery